OBJECTIVE：To evaluate the safety of acyclovir in the treatment of liver-transplanted children with EB-viremia. METHODS：Retrospectively analysis was conducted for the general information of 10 liver-transplanted children with EB-viremia， preoperative donor and recipient EBV infection and treatment，tacrolimus dose and plasma concentration before and after intervention， platelets，serum creatinine and white blood cell levels before and after treatment，and the recurrence were followed-up. RESULTS： Biliary atresia was the primary disease for all the children，EB virus polymerase chain reaction（EBV-PCR）was positive， and there was no routine testing for donor HBV infection；6 cases reduced the tacrolimus dose，4 remained unchanged，and 9 cases of plasma concentrations reduced after intervention，9 were negative and 2 recoveried. There were no significant differences in the platelets，serum creatinine and white blood cells before and after treatment（P＞0.05）. CONCLUSIONS：Acyclovir can be used in the treatment of liver-transplanted children with EB-viremia，with good safety.